Kidney Fibrosis - Pipeline Review, H1 2017

Publisher Name :
Date: 09-May-2017
No. of pages: 131
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2017, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 25 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).

  • The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Kidney Fibrosis - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kidney Fibrosis - Overview
Kidney Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kidney Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kidney Fibrosis - Companies Involved in Therapeutics Development
AbbVie Inc
Allergan Plc
Angion Biomedica Corp
Apollo Endosurgery Inc
BiOrion Technologies BV
Cellmid Ltd
Epigen Biosciences Inc
Evotec AG
Galectin Therapeutics Inc
GenKyoTex SA
Horizon Pharma Plc
Intercept Pharmaceuticals Inc
Isarna Therapeutics GmbH
MorphoSys AG
Pharmaxis Ltd
ProMetic Life Sciences Inc
Regulus Therapeutics Inc
Sirnaomics Inc
Symic Biomedical Inc
Vascular Biogenics Ltd
Kidney Fibrosis - Drug Profiles
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3586 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-4021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOT-191 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cysteamine DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Galectin-3 for Liver Fibrosis, Pulmonary Fibrosis and Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Tissue Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-136901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-4820 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5033A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEW-7197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wnt-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kidney Fibrosis - Dormant Projects
Kidney Fibrosis - Product Development Milestones
Featured News & Press Releases
Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting
Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics
Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Kidney Fibrosis - Pipeline by AbbVie Inc, H1 2017
Kidney Fibrosis - Pipeline by Allergan Plc, H1 2017
Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2017
Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc, H1 2017
Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2017
Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2017
Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2017
Kidney Fibrosis - Pipeline by Evotec AG, H1 2017
Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2017
Kidney Fibrosis - Pipeline by GenKyoTex SA, H1 2017
Kidney Fibrosis - Pipeline by Horizon Pharma Plc, H1 2017
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H1 2017
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
Kidney Fibrosis - Pipeline by MorphoSys AG, H1 2017
Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H1 2017
Kidney Fibrosis - Pipeline by Sirnaomics Inc, H1 2017
Kidney Fibrosis - Pipeline by Symic Biomedical Inc, H1 2017
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2017
Kidney Fibrosis - Dormant Projects, H1 2017

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting&hellip
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and&hellip
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries,&hellip
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the&hellip
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The&hellip
  • Asia-Pacific Hemodialysis Powder Solution Market Report 2017
    Published: 25-Jul-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the Asia-Pacific Hemodialysis Powder Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Hemodialysis Powder Solution for these regions, from 2012 to 2022 (forecast), including - China - Japan ......
  • EMEA (Europe, Middle East and Africa) Hemodialysis Powder Solution Market Report 2017
    Published: 14-Jul-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the EMEA Hemodialysis Powder Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT), revenue (Million USD), market share and growth rate of Hemodialysis Powder Solution for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Ita......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017
    Published: 11-Jul-2017        Price: US 2000 Onwards        Pages: 129
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and ches......
  • United States Hemodialysis Powder Solution Market Report 2017
    Published: 07-Jul-2017        Price: US 3800 Onwards        Pages: 104
    In this report, the United States Hemodialysis Powder Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and gr......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Acute Renal Failure (ARF) (Acute Kidney Injury) for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Acute Renal Failure (ARF) (Acute Kidney Injury) forecasted market share for ten years to......
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1500 Onwards        Pages: 70
    DelveInsight's, " Chronic Kidney Disease (Chronic Renal Failure) -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Chronic Kidney Disease (Chronic Renal Failure). The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Chronic Kidney Disease (Chronic Renal Failure). This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failu......
  • Chronic Kidney Disease (Chronic Renal Failure) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 05-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Chronic Kidney Disease (Chronic Renal Failure) - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Chronic Kidney Disease (Chronic Renal Failure) for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Chronic Kidney Disease (Chronic Renal Failure) forecasted market share for ten years to 20......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Insight, 2017
    Published: 05-Jul-2017        Price: US 1500 Onwards        Pages: 70
    DelveInsight's, " Acute Renal Failure (ARF) (Acute Kidney Injury) -Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this Acute Renal Failure (ARF) (Acute Kidney Injury). The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Acute Renal Failure (ARF) (Acute Kidney Injury). This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney ......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Epidemiology Insights to 2025
    Published: 05-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight " Acute Renal Failure (ARF) (Acute Kidney Injury) - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure (ARF) (Acute Kidney Injury) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure (ARF) (Acute Kidney Injury) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs